Associations between aortic regurgitation severity and risk of incident myocardial infarction and stroke among patients with degenerative aortic valve disease: insights from a large Chinese population-based cohort study

Guangxiao Li,1,2 Tan Li,3 Yanli Chen,1 Xiaofan Guo,1 Zhao Li,1 Ying Zhou,1 Hongmei Yang,1 Shasha Yu,1 Guozhe Sun,1 Liqiang Zheng,4 Yingxian Sun1

ABSTRACT

Objectives Few studies have explored whether the risk of myocardial infarction (MI) or stroke varies among patients with degenerative aortic valve disease (DAVD) with different severity of aortic regurgitation (AR) or not. Thus, a prospective study was conducted to elucidate the causal relationship between AR severity and risk of incident MI and stroke among patients with DAVD recruited from a general population in Northeast China.

Design Prospective cohort study.

Setting Community-based study carried out in rural areas of Northeast China.

Methods There were 3675 patients with DAVD aged ≥45 years eligible for the prospective study. During a median follow-up time of 4.64 years, 99 participants lost to follow-up. Cox regression analyses were used to investigate the association between baseline AR severity and the risk of incident MI or stroke.

Results In the final cohort of 3576 patients with DAVD, there were 3153 patients without AR (88.2%), 386 patients with mild AR (10.8%) and 37 patients with moderate/severe AR (1.0%). Multivariate analyses showed that, compared with participants without AR, those with moderate/severe AR were associated with 8.33 and 6.22-fold increased risk of MI and MI mortality, respectively. However, no significant associations between AR and the risk of stroke or stroke mortality were observed.

Conclusions As compared with no AR, moderate/severe AR but not mild AR was an independent predictor for the risk of MI and MI mortality. AR was not significantly associated with stroke or stroke mortality, irrespective of AR severity. Secondary prevention strategies should be taken to delay the progression of DAVD and thus reduce the incidence of MI.

INTRODUCTION

Over the past decades, the predominant cause of valvular heart diseases (VHDs) gradually transits from rheumatic to age-related degenerative aetiology.1 2 Degenerative VHDs have become an important public health problem that results in high morbidity and mortality in the ageing population.3 Of them, degenerative aortic valve disease (DAVD) is the most commonly observed. It was reported that the prevalence of aortic valve sclerosis, calcification or thickening was approximately 21%–31% in subjects ≥65 years of age.4 5 According to the Framingham Study, the prevalence of overall aortic regurgitation (AR) was estimated at 4.9%, while the prevalence of moderate and severe AR was 0.5%.6 The incidence and severity of AR increase with age, reaching a peak between 40 and 60 years of age.6

Strengths and limitations of this study

- Whether the risk of myocardial infarction (MI) or stroke varies across patients with degenerative aortic valve disease (DAVD) with different severity of aortic regurgitation (AR) remains unclear.
- A cohort study was conducted to elucidate the association between AR severity and risk of MI and stroke.
- The study participants were recruited using a multi-stage, randomly stratified cluster-sampling strategy.
- The diagnoses of MI were made by the local cardiologists, and not all patients with MI underwent coronary angiography.
- The relatively small number of patients with DAVD with moderate/severe AR limited the statistical power.
Accumulated evidence showed that aortic valve sclerosis and vascular atherosclerosis might share a common pathological background. The risk factors involved in the development of aortic valve sclerosis were similar to that in the development of vascular atherosclerosis, including ageing, gender, hypertension, smoking, hyperlipidaemia, diabetes.7–9 Though many studies had reported a significant association between DAVD and risk of concomitant coronary artery disease,9 10 most of them were cross-sectional or retrospective studies, which limited their ability to infer the possible causal relationship. Moreover, some previous studies were hospital-based and only enrolled patients undergoing valve replacement treatment for severe VHDs.11–13 Few studies have explored whether the risk of coexisting myocardial infarction (MI) varies among patients with DAVD with different severity of AR or not. Additionally, less is known about whether there is any significant association between AR severity and concomitant stroke among patients with DAVD. Thus, we conducted a large and prospective study to elucidate the causal relationship between AR severity and risk of MI as well as stroke among patients with DAVD (aged ≥45 years) recruited from a general Chinese population.

METHODS
Study subjects
The Northeast China Rural Cardiovascular Health Study is a community-based prospective cohort study that is carried out in rural areas of Northeast China. A full description of the study design can refer to the previous articles by our study group.14–16 In brief, a total of 11 956 participants aged ≥55 years were enrolled from three counties (Dawa, Zhangwu and Liaoyang) in Liaoning province during 2012–2013, using a multistage, randomly stratified cluster-sampling strategy. Detailed information was collected at baseline for all participants. They were invited to attend a follow-up study in 2015 and 2017, respectively. Cardiovascular events were then collected and evaluated. Participants who completed at least one follow-up visit were considered successfully followed up.

As shown in figure 1, the participants were further screened depending on the purpose of the current study. Of the 11 956 participants, 2803 participants were excluded because they were aged <45 years. Furthermore, participants who did not undergo transthoracic echocardiogram (TTE) or had not DAVD were excluded (n=230 and n=4762, respectively). Participants with endocarditis, rheumatic or congenital heart disease were also excluded (n=6). Participants who did not agree to complete the follow-up visits at baseline were excluded as well (n=480). Finally, there were 3675 patients with DAVD eligible for the prospective study.

Data collection
At baseline, all research subjects were interviewed face-to-face by cardiologists and nurses using a standardised questionnaire. Detailed information on demographic characteristics, cardiovascular risk factors and medical records was obtained. History of MI, atrial fibrillation (AF), heart failure and stroke was self-reported and further confirmed by medical records. Usage of anti-hypertensive and antidiabetic drugs within 2 weeks at baseline was self-reported as well. Blood pressure was measured three times in a resting state with an interval of at least 5 min using a standardised automatic electronic sphygmomanometer (HEM-907; Omron, Tokyo, Japan). The average value was used for statistical analysis. To accurately measure height and weight, all study subjects should take off their shoes and wear light clothes. Fasting blood samples were collected by trained nurses after fasting for at least 12 hours. Fasting plasma glucose (FPG), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum creatinine, calcium and phosphorus were measured automatically (Olympus AU 640, Tokyo, Japan).

Hypertension was defined as systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Participants who were taking antihypertensive drugs were also diagnosed as hypertension. Diabetes was defined as FPG≥7.0 mmol/L,17 with known

Figure 1 The flowchart for the selection of study subjects. AR, aortic regurgitation; DAVD, degenerative aortic valve disease; TTE, transthoracic echocardiogram.
diabetes, or current use of antidiabetic drugs. The lipid profiles that met at least one of the following criteria would be diagnosed as dyslipidaemia: TC ≥ 6.21 mmol/L, TG ≥ 2.26 mmol/L, LDL-C ≥ 4.16 mmol/L or HDL-C < 1.03 mmol/L. The estimated glomerular filtration rate (eGFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation.19

**Electrocardiographic evaluation**

As previously described, baseline echocardiogram was conducted by using the commercially available Doppler echocardiographic machine (Vivid, GE Healthcare, Chicago, USA), with 3.0-MHz transducer.20 The TTE included M-mode, two-dimensional, spectral and colour Doppler. All participants were examined in the lateral position. The echocardiograms were analysed and read by three experienced sonographers specialised in echocardiography. Any discrepancy would be resolved by discussion.

DAVD was defined as an abnormal irregular thickening or a focal or diffuse increase of the echogenicity of the leaflets with or without reduced systolic opening.4 The colour flow Doppler enables the visualisation of the actual regurgitant jet.21 The severity of AR was estimated by the ratio of the regurgitant jet width to the LV outflow tract in the centrally directed jet.22 A ratio of <25%, 25%–64% and ≥65% indicate mild, moderate and severe AR, respectively.22 Similarly, tricuspid and mitral valve regurgitation was judged by the existence of the regurgitant jet or not. The assessment of valve stenosis (including tricuspid stenosis, mitral stenosis and aortic stenosis) was conducted according to the European Association of Echocardiography (EAE)/American Society of Echocardiography (ASE) recommendations for clinical practice.23

The measurements of aortic annular diameter (AOD), interventricular septal thickness (IVSd), LV end-diastolic internal dimension (LVIDd), LV end-systolic internal dimension (LVIDs) and posterior wall thickness were performed following the guideline of the ASE.24 Left ventricular mass (LVM) was calculated using a corrected formula derived from the ASE-cube LV mass formula.25 LVM=0.8×(1.04×(IVSd+LVIDd+PWTd)−LVIDd)³+0.6 g. The LVM index (LVMi) was estimated as a ratio of LVM to body surface area. The LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV) were calculated using the equation developed by Teichholz et al.26 Stroke volume (SV) was equal to LVEDV−LVESV. LV ejection fraction (LVEF) was calculated as ((LVEDV−LVESV) / LVEDV)×100%.

**Definition of endpoints**

The clinical outcome of the current study was the presence of new-onset MI or stroke during the follow-up period, irrespective of the prior history. MI and stroke specific mortality was also recorded. MI was diagnosed following the third universal definition of MI.27 According to the WHO Multinational Monitoring of Trends and Determinants in Cardiovascular Disease criteria,28 stroke was defined as the rapid development of focal or global cerebral function disturbance lasting >24 hour (unless interrupted by surgery or mortality), without apparent non-vascular causes. Haemorrhagic stroke was defined as the bursting of the blood vessel, consisted of intracerebral haemorrhage and subarachnoid haemorrhage. Ischaemic stroke was defined as a stroke with thrombosis or embolism. Transient ischaemic attack and chronic cerebral vascular disease were not included.

For all study subjects reporting possible diagnoses or mortality, all available clinical information was gathered, including medical records and death certificates. The diagnoses of any cardiovascular events should be made in a secondary hospital or upper grade of hospital by patients’ attending physicians. All materials were further reviewed and judged by the endpoint assessment committee.16

**Patient and public involvement statement**

It was not appropriate or possible to involve patients or the public in the design, or conduct, or reporting, or dissemination plans of our research.

**Statistical analysis**

Continuous data were summarised as means±SD and the linear trend across different AR severity groups was examined using the linear term of analysis of variance (ANOVA) test. Categorical data were expressed as counts (%) and the linear trend across different AR severity groups was estimated using the linear-by-linear association of $\chi^2$ test or Fisher’s exact test, as appropriate. Cumulative incidences of MI, MI mortality, stroke and stroke mortality were depicted using the Kaplan-Meier curves. The differences in cumulative incidences across different AR severity groups were examined using the log-rank test. The HRs and their corresponding 95% CIs of AR severity on risk of clinical outcomes were calculated using Cox proportional hazard models, adjusting for age, sex, BMI, smoking, drinking, hypertension, diabetes, history of MI, history of AF, history of heart failure, history of stroke, dyslipidaemia, eGFR, calcium, phosphorus, aortic peak velocity, LVMi and LVEF, as appropriate. Sensitivity analysis was conducted by excluding participants with a history of MI or stroke at baseline to further confirm the causal relationship.

All statistical analyses were performed using SPSS V.22.0 software (IBM Corporation, Chicago, Illinois, USA). Missing data were handled using the multiple imputation method. Kaplan-Meier curves were drawn using GraphPad Prism V.8.0 for Windows (GraphPad Software, La Jolla, California, USA). The forest plot was depicted using R software V.3.6.3 (R Core Team, 2020). All tests were two-tailed and p value <0.05 was considered statistically significant.
RESULTS
Baseline clinical and echocardiographic characteristics of patients with DAVD with different AR severity

Baseline clinical characteristics of the participants diagnosed with patients with DAVD were grouped according to the AR severity in table 1. Of the final cohort of 3576 patients with DAVD, there were 3153 patients without AR (88.2%), 386 patients with mild AR (10.8%) and 37 patients with moderate or severe AR (1.0%). As shown in table 1, patients with DAVD with mild AR or moderate/severe AR were older and more likely to be men, as compared with patients with DAVD without AR ($P_{\text{trend}} < 0.01$ and $P_{\text{trend}} < 0.001$, respectively). The DBP level declined gradually with increasing severity of AR ($P_{\text{trend}} < 0.01$). In contrast, the prevalence of hypertension increased across different AR severity groups ($P_{\text{trend}} < 0.01$). Significant trends were not observed for BMI, smoking, drinking, SBP, heart rate, antihypertensive drugs, diabetes and antidiabetic drugs across different AR severity groups (all with $P_{\text{trend}} > 0.05$). The history of heart failure and stroke across the three groups was comparable, but not for the history of MI or AF ($P_{\text{trend}} = 0.02$ and $P_{\text{trend}} = 0.01$, respectively). There were no linear trends in the levels of TC, TG, LDL-C, HDL-C, FPG, calcium and phosphorus (all with $P_{\text{trend}} > 0.05$), while the proportion of dyslipidaemia and the level of eGFR decreased with the worsening of AR ($P_{\text{trend}} = 0.03$ and $P_{\text{trend}} < 0.01$, respectively).

| Variables                  | AR severity                        | $P_{\text{trend}}$ |
|----------------------------|------------------------------------|---------------------|
|                            | No AR ($n=3153$)                   | Mild AR ($n=386$)   | Moderate or severe AR ($n=37$) |
| Age, y                     | 61.59±8.13                        | 64.36±9.55          | 65.98±8.83                      |
| Sex (male), n (%)          | 1305 (41.4)                       | 238 (61.7)          | 18 (48.6)                       |
| BSA, m$^2$*                | 1.61±0.17                         | 1.62±0.17           | 1.59±0.19                       |
| BMI, kg/m$^2$*             | 24.65±3.79                        | 24.23±3.54          | 23.84±3.08                      |
| Smoking, n (%)             | 1113 (35.3)                       | 148 (38.3)          | 13 (35.1)                       |
| Drinking, n (%)            | 600 (19.0)                        | 99 (25.6)           | 6 (16.2)                        |
| SBP, mm Hg*                | 148.97±24.43                      | 154.00±32.20        | 146.58±21.11                    |
| DBP, mm Hg*                | 83.05±12.02                       | 82.42±12.12         | 76.80±9.62                      |
| Pulse pressure, mm Hg      | 65.92±18.91                       | 71.58±21.43         | 69.78±17.60                     |
| Heart rate, bmp*           | 79.13±14.09                       | 76.89±14.15         | 78.83±11.37                     |
| Hypertension, n (%)        | 2028 (64.3)                       | 277 (71.8)          | 25 (67.6)                       |
| Antihypertensive drugs, n (%) | 689 (21.9)                       | 92 (23.8)           | 11 (29.7)                       |
| Diabetes, n (%)            | 433 (13.7)                        | 49 (12.7)           | 8 (21.6)                        |
| Antidiabetic drugs, n (%)  | 157 (5.0)                         | 23 (6.0)            | 3 (8.1)                         |
| History of MI              | 49 (1.6)                          | 13 (3.4)            | 1 (2.7)                         |
| History of AF              | 44 (1.4)                          | 8 (2.1)             | 3 (8.1)                         |
| History of heart failure   | 47 (1.5)                          | 9 (2.3)             | 1 (2.7)                         |
| History of stroke          | 197 (6.2)                         | 24 (6.2)            | 2 (5.4)                         |
| TC, mmol/L*                | 5.43±1.11                         | 5.29±1.16           | 5.22±0.95                       |
| TG, mmol/L*                | 1.63±1.32                         | 1.52±1.05           | 1.28±0.62                       |
| LDL-C, mmol/L*             | 3.09±0.85                         | 3.02±0.93           | 2.94±0.73                       |
| HDL-C, mmol/L*             | 1.44±0.40                         | 1.46±0.41           | 1.50±0.36                       |
| Dyslipidaemia, n (%)       | 1235 (39.2)                       | 138 (35.8)          | 8 (21.6)                        |
| eGFR, ml/min.1.73 m$^2$    | 87.22±14.44                       | 86.26±14.42         | 79.68±15.04                     |
| FPG, mmol/L*               | 6.08±1.85                         | 5.99±1.71           | 6.17±1.33                       |
| Calcium, mmol/L*           | 2.33±0.13                         | 2.32±0.12           | 2.30±0.13                       |
| Phosphorus, mmol/L*        | 1.14±0.18                         | 1.09±0.17           | 1.11±0.17                       |

*Missing values: BSA or BMI 30 cases; SBP, DBP or heart rate, 31 cases; TC, TG, LDL-C or HDL-C, 29 cases; eGFR, 29 cases; FPG, 29 cases; calcium, 29 cases; phosphorus, 30 cases. Missing values were filled using multiple imputation method.

AF, atrial fibrillation; AR, aortic regurgitation; BMI, body max index; BSA, body surface area; DAVD, degenerative aortic valve disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
At baseline, patients with DAVD with more severe AR were more likely to have elevated AOD, aortic peak velocity, IVSd, LVIDd, LVIDs, PWTd, LVM, LVMI, LVEDV, LVESV and SV (Table 2). In addition to AR, the most common concomitant VHD was the mitral regurgitation (150/3576, 4.2%), followed by the tricuspid regurgitation (108/3576, 3.0%). Whereas, only a few patients with DAVD had concomitant mitral stenosis (3/3576, 0.1%) and aortic stenosis (9/3576, 0.3%). None of the patients with DAVD had concomitant tricuspid stenosis. Furthermore, the prevalence of concomitant VHDs increased with the worsening degree of AR (all with P trend <0.001).

**Table 2** Baseline echocardiographic characteristics for patients with DAVD stratified by AR severity

| Variables                        | AR severity            | P trend |
|----------------------------------|------------------------|---------|
|                                 | No AR (n=3153)         |         |
|                                 | Mild AR (n=386)        |         |
|                                 | Moderate or severe AR (n=37) |         |
| Echocardiographic data           |                        |         |
| AOD, cm*                         | 2.26±0.28              | <0.01   |
| Aortic peak velocity, cm/s*      | 120.41±24.44           | <0.001  |
| IVSd, cm                         | 0.90±0.12              | <0.001  |
| LVIDd, cm                        | 4.70±0.42              | <0.001  |
| LVIDs, cm                        | 3.11±0.43              | <0.001  |
| PWTd, cm*                        | 0.87±0.11              | <0.001  |
| LVM, g                           | 141.58±36.70           | <0.001  |
| LVMI, g/m²                      | 87.95±20.21            | <0.001  |
| LVEDV, mL                       | 103.53±21.91           | <0.001  |
| LVESV, mL                       | 39.30±13.22            | <0.001  |
| SV, mL                           | 64.23±17.55            | <0.001  |
| LVEF, %                          | 61.94±10.05            | 0.38     |
| Other concomitant VHD            |                        |         |
| Tricuspid stenosis, n (%)        | 0 (0)                  | –       |
| Tricuspid regurgitation, n (%)   | 82 (2.6)               | <0.001  |
| Mitral stenosis, n (%)           | 0 (0)                  | <0.001  |
| Mitral regurgitation, n (%)      | 108 (3.4)              | <0.001  |
| Aortic stenosis, n (%)           | 4 (0.1)                | <0.001  |

*Missing values: AOD, 5 cases; aortic peak velocity, 3 cases; PWTd, 4 cases; LVM, 4 cases; LVMI, 34 cases. Missing values were filled using multiple imputation method.

AOD, aortic annular diameter; AR, aortic regurgitation; DAVD, degenerative aortic valve disease; IVSd, interventricular septal thickness; LVEDV, LV end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, LV end-systolic volume; LVIDd, LV end-diastolic internal diameter; LVIDs, LV end-systolic internal dimension; LVM, left ventricular mass; LVMI, left ventricular mass index; PWTd, posterior wall thickness; SV, stroke volume; VHD, valvar heart disease.

*Crude incidence of clinical outcomes among patients with DAVD with different AR severity

Table 3 lists the crude incidences of MI, MI mortality, stroke and stroke mortality. A significant stepwise increase in MI (1.2% vs 2.3% vs 16.2%, P trend <0.001) and MI mortality (0.8% vs 1.8% vs 13.5%, P trend <0.001) was observed in the transition from no AR to moderate/severe AR. However, our results failed to show any significant trend in the stroke or stroke mortality incidence across different AR severity groups (both with P trend >0.05). Stratified analyses by stroke types showed similar findings as well.

**Kaplan-Meier curves for the cumulative incidence of clinical outcomes with different AR severity

The Kaplan-Meier curves for each endpoint in patients with DAVD with different AR severity are shown in figure 2. Higher cumulative incidences of MI and MI mortality were observed among patients with DAVD with moderate or severe AR, as compared with those without AR or mild AR (both with log-rank test p<0.001). However, the differences in the incidences of stroke or stroke mortality for the three AR severity groups were not statistically significant (log-rank p=0.22 and p=0.30, respectively).

Kaplan-Meier curves for the cumulative incidence of clinical outcomes with different AR severity

Cox regression analyses for the prognostic significance of AR severity among patients with DAVD

Figure 3 shows the multivariate-adjusted HRs and their corresponding 95% CIs for the MI, MI mortality, stroke and stroke mortality, respectively. Moderate/severe AR was independently associated with a 8.33 and 6.22-fold increased risk of MI and MI mortality as compared with
no AR (MI, HR=8.33, 95% CI: 2.96 to 23.49, p<0.001; MI mortality, HR=6.22, 95% CI: 2.07 to 18.70, p<0.01). However, the associations between mild AR and the risk of MI and MI mortality were not statistically significant when compared with no AR (p=0.25 and p=0.08, respectively). Neither mild AR nor moderate/severe AR was associated with an elevated risk of stroke or stroke mortality, compared with no AR. Furthermore, to establish the causal relationship, Cox regression analyses investigating the AR severity on risk of different clinical outcomes were further conducted by excluding patients with DAVD with prior history of MI or stroke at baseline. The associations between moderate/severe AR and risk of MI and MI mortality remained statistically significant (MI, HR=8.40, 95% CI: 2.98 to 23.67, p<0.01; MI mortality, HR=6.56, 95% CI: 2.20 to 19.56, p<0.01).

**DISCUSSION**

Of the 3576 patients with DAVD recruited from a general Chinese population, 423 patients (11.8%) had concomitant AR. The linear trends were significant for age, sex proportion, DBP, hypertension, prior MI, AF, dyslipidaemia and eGFR across different AR groups. All echocardiographic parameters and prevalence of other coexisting VHDS significantly increased with the worsening degree of AR except for the level of LVEF. Multivariate Cox regression analyses showed that, compared with participants without AR, those with moderate/severe AR were associated with 8.33 and 6.22-fold increased risk of MI and MI mortality, respectively. However, the associations between moderate/severe AR and the risk of stroke or stroke mortality were not significant (p=0.75 and 0.93, respectively).

**Table 3** Crude incidence of clinical outcomes among patients with DAVD with different AR severity

| Outcomes                  | Incidence                         | P_trend |
|---------------------------|-----------------------------------|---------|
|                          | No AR (n=3153)                    |         |
| MI, n (%)                 | 39 (1.2)                          |         |
| MI mortality, n (%)       | 25 (0.8)                          |         |
| Stroke, n (%)*            | 192 (6.1)                         |         |
| Ischaemic stroke, n (%)   | 145 (4.6)                         |         |
| Haemorrhagic stroke, n (%)| 38 (1.2)                          |         |
| Stroke mortality, n (%)*  | 76 (2.4)                          |         |
| Ischaemic stroke, n (%)   | 34 (1.1)                          |         |
| Haemorrhagic stroke, n (%)| 33 (1.0)                          |         |
|                          | Mild AR (n=386)                   |         |
| MI, n (%)                 | 9 (2.3)                           |         |
| MI mortality, n (%)       | 7 (1.8)                           |         |
| Stroke, n (%)*            | 20 (5.2)                          | 1.00    |
| Ischaemic stroke, n (%)   | 14 (3.6)                          | 0.91    |
| Haemorrhagic stroke, n (%)| 5 (1.3)                           | 0.68    |
| Stroke mortality, n (%)*  | 9 (2.3)                           | 0.65    |
| Ischaemic stroke, n (%)   | 5 (1.3)                           | 0.51    |
| Haemorrhagic stroke, n (%)| 3 (0.8)                           | 1.00    |
|                          | Moderate or severe AR (n=37)      |         |
| MI, n (%)                 | 6 (16.2)                          | <0.001  |
| MI mortality, n (%)       | 5 (13.5)                          | <0.001  |
| Stroke, n (%)*            | 4 (10.8)                          |         |
| Ischaemic stroke, n (%)   | 3 (8.1)                           |         |
| Haemorrhagic stroke, n (%)| 1 (2.7)                           |         |

*10 cases had unknown stroke type.

AR, aortic regurgitation; DAVD, degenerative aortic valve disease; MI, myocardial infarction.
respectively). Meanwhile, the risk of all clinical outcomes in the mild AR group was similar to that in the no AR group (all with p>0.05).

Interestingly, we found that the most prevalent concomitant VHD was AR rather than AS in our study population (11.8% vs 0.25%), which was greatly different from that in the Western population.1 Our findings were consistent with the conclusion of a previous population-based study from China.29 In that study, the detection rates of moderate or severe AR were much higher than those of AS in two different age groups (65–64 years: 2.12% vs 0.75%; ≥75 years: 2.85% vs 0.89%), involving 49 995 cases and 34 671 cases, respectively.29 In our study, the prevalence of moderate or severe AR among 3576 patients with DAVD aging ≥45 years was 1.03%, which was far higher when compared with that of AS (0.25%). Similarly, another Chinese study based on the elderly population indicated that the most frequent VHD was AR, followed by tricuspid regurgitation and mitral regurgitation.30 The discrepancies in prevalence rates of VHDs might partly be attributable to the differences in diagnostic criteria, data sources (population-based or hospital-based), clinical characteristics and year of data collection.30 Nevertheless, our results did suggest that the spectrum of VHDs was different between the Western and Chinese populations to some extent. Thus, more attention should be paid to this characteristic in future transcatheter aortic valve replacement (TAVR) device designs for the treatment of AR.29

The severity of DAVD progresses with age. Degenerative AR was more common in men than women, which was in accordance with findings from a previous study.31 According to the haemodynamics of AR, severe AR reveals a widened pulse pressure from increased SV and elevated SBP but a rapid decline in DBP. In our study, SV and DBP showed a significant linear trend as the AR deteriorates. However, the linear trend was not found for SBP across different AR groups. As reported in published literature, VHDs such as aortic stenosis and mitral regurgitation were predictors of AF.33 Our results indicated that moderate/severe AR was significantly associated with a high prevalence of AF (8.2%). The eGFR gradually declined with the increasing severity of AR. Previous studies suggested that the presence of chronic kidney disease might accelerate and amplify the process of aortic valve calcification via multiple mechanisms, such as inflammation, anaemia, oxidative stress, haemodynamic overload and abnormal calcium/phosphate metabolism even if serum calcium/phosphate levels are within normal ranges.34–36

| Outcomes                  | Cases/Noncases | HR (95% CI) | p value |
|---------------------------|----------------|-------------|---------|
| MI                        |                |             |         |
| No AR                     | 39/3114        | Reference   |         |
| Mild AR                   | 9/377          | 1.69 (0.79, 3.64) | 0.18    |
| Moderate/severe AR        | 6/318.33       | 2.96, 23.49  | <0.001  |
| MI mortality              |                |             |         |
| No AR                     | 25/128         | Reference   |         |
| Mild AR                   | 7/379          | 1.89 (0.88, 4.06) | 0.1     |
| Moderate or severe AR     | 5/322.62       | 2.07, 18.70  | <0.01   |
| MI#                       |                |             |         |
| No AR                     | 38/3066        | Reference   |         |
| Mild AR                   | 7/366          | 1.48 (0.64, 3.43) | 0.36 |
| Moderate or severe AR     | 6/308.40       | 2.98, 23.67  | <0.001  |
| Stroke                    |                |             |         |
| No AR                     | 192/2961       | Reference   |         |
| Mild AR                   | 20/366         | 0.63 (0.39, 1.00) | 0.05 |
| Moderate or severe AR     | 4/33           | 1.18 (0.42, 3.35) | 0.75 |
| Stroke mortality          |                |             |         |
| No AR                     | 76/3077        | Reference   |         |
| Mild AR                   | 9/377          | 0.60 (0.30, 1.23) | 0.16 |
| Moderate or severe AR     | 2/35           | 0.93 (0.21, 4.19) | 0.93 |
| Stroke#                   |                |             |         |
| No AR                     | 170/2786       | Reference   |         |
| Mild AR                   | 20/342         | 0.71 (0.44, 1.14) | 0.16 |
| Moderate or severe AR     | 2/33           | 0.52 (0.12, 2.20) | 0.38 |
| Stroke mortality#         |                |             |         |
| No AR                     | 64/2892        | Reference   |         |
| Mild AR                   | 9/353          | 0.72 (0.35, 1.49) | 0.38 |
| Moderate or severe AR     | 2/33           | 1.01 (0.22, 4.68) | 0.99 |

Figure 3 The adjusted HRs and the corresponding 95% CIs for the associations between AR severity and risk of different clinical outcomes among patients with DAVD. Adjusted for age, sex, BMI; smoking, drinking, hypertension, diabetes, history of MI, history of AF, history of heart failure, history of stroke, dyslipidaemia, eGFR, calcium, phosphorus, AOD, aortic peak velocity, LVMi and LVEF as appropriate. AF, atrial fibrillation; AR, aortic regurgitation; AOD, aortic annular diameter; BMI, body mass index; DAVD, degenerative aortic valve disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; MI, myocardial infarction. Participants with history of MI or stroke at baseline were excluded as appropriate.
AR can not only result from malfunction of the aortic leaflets themselves, but also from the dilatation of the aortic root and annulus, or both. Thus, increased AOD was observed in patients with DAVD with worsening AR. Furthermore, as the degree of AR became more severe, the SV increased, which would cause a rise in aortic peak velocity. Additionally, the chronic volume overload due to AR allows for a compensatory remodelling of the left ventricle (LV) characterised as eccentric hypertrophy of the cardiac myocytes and chamber dilatation. This allows for the balance of LV systolic function and prevents sudden elevation in end-diastolic pressure. As AR worsens, the LV remodelling worsens, resulting in increased interstitial fibrosis and decreased LV compliance, elevated end-systolic volume, elevated end-diastolic pressure, further cardiac enlargement and impaired systolic function. The above haemodynamic and anatomical changes were supported by the echocardiographic parameters in table 2.

As compared with no AR, moderate/severe AR but not mild AR was an independent predictor of the risk of MI and MI mortality. AR was not significantly associated with stroke or stroke mortality. Previous evidence suggested that DAVD was an atherosclerosis-like process involving the aortic valve, in which DAVD and atherosclerosis shared a common pathogenic mechanism. Therefore, predictive factors of aortic sclerosis were risk factors of atherosclerosis as well. The severity of aortic valve lesions was positively correlated with the burden of atherosclerotic lesions, accounting for the linear trend of MI risk among patients with DAVD across different AR severity. The myocardial hypertrophy resulted from AR can lead to an imbalance between myocardial oxygen supply and demand. Furthermore, the elevated LV end-diastolic pressure and shortened diastole from tachycardia change the coronary flow dynamics, decreasing the coronary perfusion, and thus aggravating coronary artery ischaemia. Perhaps that’s why moderate/severe AR was significantly related to the risk of MI rather than the risk of stroke.

Strengths and limitations
One strength of the current study is that patients with DAVD were recruited from a large population of Northeastern China. Moreover, our study was prospectively conducted and the clinical outcomes were identified during the follow-up period, which enables the inference of a causal relationship between AR severity and risk of clinical outcomes.

Despite the strengths mentioned above, our study has several limitations. First, the diagnoses of MI were made by the local cardiologists, and not all patients with MI underwent coronary angiography. This might have led to overdiagnosis of MI. Second, although there were 3576 patients with DAVD involved in the current study, the number of patients with DAVD with moderate/severe AR is relatively small (n=37), which limited the statistical power to some extent. Considering the fact that the participants were enrolled from a general population, it is therefore not surprising. Finally, patients with DAVD who had a history of MI or stroke were not excluded at baseline, which restricted the causal inference. However, the sensitivity analysis showed that the associations between moderate/severe AR and risk of MI and MI mortality remained significant even after the exclusion of baseline MI.

Conclusions
AR was the most prevalent concomitant VHD among patients with DAVD from a Chinese general population. Moderate/severe AR but not mild AR was strongly associated with the risk of MI and MI mortality, independent of traditional risk factors. However, there was no evidence that AR was significantly associated with stroke, irrespective of AR severity. As DAVD and share many common pathophysiological pathways with atherosclerosis, secondary prevention strategies targeting these pathways should be taken to delay the progression of DAVD and thus reduce the incidence of MI.

Author affiliations
1Department of Cardiology, The First Hospital of China Medical University, Shenyang, China
2Department of Medical Record Management Center, The First Hospital of China Medical University, Shenyang, China
3Department of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, China
4Department of Clinical Epidemiology, Library, Shengjing Hospital of China Medical University, Shenyang, China

Contributors ZL and YS contributed to the conception and design of the study. GL, YZ, HY, SY, GS and LZ contributed to the acquisition, analysis or interpretation of data for the study. GL drafted the manuscript. TL, XG and YC critically revised the manuscript. All authors have reviewed the final version of the manuscript and approved it for publication.

Funding This study was supported by the National Natural Science Foundation of China (Grant#81800381, Grant#81700322) and National Key Research and Development Program of China (Grant#2017YFC1307600).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The study was approved by the Ethics Committee of China Medical University (Shenyang, China AF-SDP-07-1, 0-01). Written informed consent was obtained from all participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data are available from the corresponding author upon reasonable request and with permission of the Northeast China Rural Cardiovascular Health Study group.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Guangxiao Li http://orcid.org/0000-0003-0319-3490
Liqiang Zheng http://orcid.org/0000-0003-0101-0398
Yingxian Sun http://orcid.org/0000-0002-1961-899X
REFERENCES
1. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. *Nat Rev Cardiol* 2011;8:162–72.
2. Steiner JM, Cooper S, Kirkpatrick JN. Palliative care in end-stage valvular heart disease. *Heart* 2017;103:1233–7.
3. Rostagno C. Heart valve disease in elderly. *World J Cardiol* 2019;11:71–83.
4. Stritzke J, Linsel-Nitschke P, Markus MRP, et al. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. *Eur Heart J* 2009;30:2044–53.
5. Bhatia N, Basra SS, Skolnick AH, et al. Aortic valve disease in the older adult. *J Geriatr Cardiol* 2016;13:941–4.
6. Mauer G. Aortic regurgitation. *Heart* 2006;92:994–1000.
7. Iung B. Interface between valve disease and ischaemic heart disease. *Heart* 2000;84:347–52.
8. Rossi A, Bertagnolli G, Cicioara M, et al. Association of aortic valve sclerosis and coronary artery disease in patients with severe nonischemic mitral regurgitation. *Clin Cardiol* 2003;26:579–82.
9. Chadha DS, Malani SK, Bharadwaj P, et al. Risk factors for degenerative aortic valve disease in India: a case control study. *Med J Armed Forces India* 2018;74:33–7.
10. Rossi A, Gaibazzi N, Dandale R, et al. Aortic valve sclerosis as a marker of coronary artery atherosclerosis; a multicenter study of a large population with a low prevalence of coronary artery disease. *Int J Cardiol* 2014;172:364–7.
11. Matta A, Moussallem N. Coronary artery disease is associated with valvular heart disease, but could it be a predictive factor? *Indian Heart J* 2019;71:284–7.
12. Emren ZY, Emren SV, Kılıçaslan B, et al. Evaluation of the prevalence of coronary artery disease in patients with valvular heart disease. *J Cardiothorac Surg* 2014;9:153.
13. Höllriegel R, Linke A, Hochadel M, et al. Impact of coronary artery disease on in-hospital mortality in patients with aortic valve disease. Results from the German ALIK registry. * Herz* 2013;38:387–90.
14. Li Z, Guo X, Zheng L, et al. Prehypertension in rural northeastern China: results from the Northeast China rural cardiovascular health study. *J Clin Hypertens* 2014;16:664–70.
15. Li Z, Guo X, Zheng L, et al. Grim status of hypertension in rural China: results from Northeast China rural cardiovascular health study 2013. *J Am Soc Hypertens* 2015;9:558–64.
16. Guo X, Li Z, Zhou Y, et al. The effects of transitions in metabolic health and obesity status on incident cardiovascular disease: insights from a general Chinese population. *Eur J Prev Cardiol* 2020;24:74873201955550.
17. Diabetes Canada Clinical Practice Guidelines Expert Committee, Punthakee Z, Goldenberg R, et al. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. *Can J Diabetes* 2018;42:510–15.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA* 2001;285:2486–97.
19. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–12.
20. Li T, Yang J, Guo X, et al. Geometrical and functional changes of left heart in adults with prehypertension and hypertension: a cross-sectional study from China. *BMC Cardiovasc Disord* 2016;16:114.
21. Akinseye OA, Pathak A, Ibebuogu UN. Aortic valve regurgitation: a comprehensive review. *Curr Probl Cardiol* 2018;43:315–34.
22. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of echocardiography developed in collaboration with the Society for cardiovascular magnetic resonance. *J Am Soc Echocardiogr* 2017;30:303–71.
23. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *Eur J Echocardiogr* 2009;10:1–25.
24. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of echocardiography and the European association for cardiovascular imaging. *J Am Soc Echocardiogr* 2015;28:1–39.
25. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol* 1986;57:450–8.
26. McFadzien JS, O’Donnell J, Krum H, et al. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. *Am J Cardiol* 1976;37:7–11.
27. White H, Thygesen K, Alpert JS, et al. Universal MI definition update for cardiovascular disease. *Curr Cardiol Rep* 2014;16:492.
28. Zhao D, Liu J, Wang W, et al. Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing project. *Stroke* 2008;39:1668–74.
29. Park Y, Zhou D, Cheng J, et al. Aortic valve surgery is more prevalent than aortic stenosis in Chinese elderly population: implications for transcatheter aortic valve replacement. *Int J Cardiol* 2015;201:547–8.
30. Shu C, Chen S, Qin T, et al. Prevalence and correlates of valvular heart diseases in the elderly population in Hubei, China. *Sci Rep* 2016;6:22753.
31. Cramariuc D, Rogge BP, Lonnebakken MT, et al. Sex differences in cardiovascular outcome during progression of aortic valve stenosis. *Heart* 2015;101:209–14.
32. Stouffer GA, Uretsky BF. Hemodynamic changes of aortic regurgitation. *Am J Med Sci* 1997;314:411–4.
33. Widgren V, Dencker M Fau - Juhlin T, Juhlin T Fau - Platovov P, et al. Aortic stenosis and mitral regurgitation as predictors of atrial fibrillation during 11 years of follow-up. *BMC Cardiovasc Disord* 2012;12:92.
34. Matsuda T, Dohi K, Sakurai Y, et al. Impact of chronic kidney disease on the presence and severity of aortic stenosis in patients at high risk for coronary artery disease. *Cardiovasc Ultrasound* 2011;9:31.
35. Perkovic V, Hunt D, Griffin SV, et al. Accelerated progression of calcific aortic stenosis in dialysis patients. *Nephron Clin Pract* 2009;103:40–5.
36. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. *Am J Kidney Dis* 1996;27:394–401.
37. Bekeredjian R, Grayburn PA. Valvular heart disease: aortic regurgitation. *Circulation* 2005;112:125–34.
38. Masuyama T, Kodama K, Kitabatake A, et al. Noninvasive evaluation of aortic regurgitation by continuous-wave Doppler echocardiography. *Circulation* 1986;73:460–6.
39. Barletta G, Di Donato M, Baroni M, et al. Left ventricular remodeling in chronic aortic regurgitation. *Int J Card Imaging* 1993;3:185–93.
40. Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. *J Am Coll Cardiol* 2001;38:827–34.
41. Pathak R, Padmanabhan VT, Tortolani AJ, et al. Angina pectoris and coronary artery disease in isolated, severe aortic regurgitation. *Am J Cardiol* 1986;57:649–51.
42. Nguyen T, Do H, Pham T, et al. Left ventricular dysfunction causing ischemia in patients with patent coronary arteries. *Perfusion* 2018;33:115–22.